Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in TSC1 and TSC2. Conventional DNA diagnostic screens identify a TSC1 or TSC2 mutation in 75 - 90% of individuals categorised with definite TSC. The remaining individuals either have a mutation that is undetectabl...

Full description

Saved in:

Bibliographic Details
Published in:	BMC medical genetics 2015-02, Vol.16 (1), p.10-10, Article 10
Main Authors:	Nellist, Mark, Brouwer, Rutger W W, Kockx, Christel E M, van Veghel-Plandsoen, Monique, Withagen-Hermans, Caroline, Prins-Bakker, Lida, Hoogeveen-Westerveld, Marianne, Mrsic, Alan, van den Berg, Mike M P, Koopmans, Anna E, de Wit, Marie-Claire, Jansen, Floor E, Maat-Kievit, Anneke J A, van den Ouweland, Ans, Halley, Dicky, de Klein, Annelies, van IJcken, Wilfred F J
Format:	Article
Language:	eng
Subjects:	Adolescent Child DNA Mutational Analysis Genetic Loci - genetics Genomics High-Throughput Nucleotide Sequencing Humans Middle Aged Mutation Tuberous Sclerosis - genetics Tumor Suppressor Proteins - genetics
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in TSC1 and TSC2. Conventional DNA diagnostic screens identify a TSC1 or TSC2 mutation in 75 - 90% of individuals categorised with definite TSC. The remaining individuals either have a mutation that is undetectable using conventional methods, or possibly a mutation in another as yet unidentified gene. Here we apply a targeted Next Generation Sequencing (NGS) approach to screen the complete TSC1 and TSC2 genomic loci in 7 individuals fulfilling the clinical diagnostic criteria for definite TSC in whom no TSC1 or TSC2 mutations were identified using conventional screening methods. We identified and confirmed pathogenic mutations in 3 individuals. In the remaining individuals we identified variants of uncertain clinical significance. The identified variants included mosaic changes, changes located deep in intronic sequences and changes affecting promoter regions that would not have been identified using exon-only based analyses. Targeted NGS of the TSC1 and TSC2 loci is a suitable method to increase the yield of mutations identified in the TSC patient population.
ISSN:	1471-2350 1471-2350